Shares of Surmodics, Inc. (NASDAQ:SRDX - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $31.19 and traded as high as $31.53. Surmodics shares last traded at $30.21, with a volume of 67,548 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th.
Get Our Latest Stock Report on Surmodics
Surmodics Stock Performance
The stock's fifty day moving average is $29.41 and its 200-day moving average is $31.07. The company has a quick ratio of 3.99, a current ratio of 5.14 and a debt-to-equity ratio of 0.27. The stock has a market cap of $456.31 million, a price-to-earnings ratio of -22.96 and a beta of 1.31.
Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). Surmodics had a negative net margin of 16.34% and a negative return on equity of 7.10%. The company had revenue of $28.09 million during the quarter, compared to the consensus estimate of $32.23 million. On average, analysts forecast that Surmodics, Inc. will post 0.2 EPS for the current year.
Institutional Investors Weigh In On Surmodics
A number of large investors have recently added to or reduced their stakes in SRDX. Legal & General Group Plc boosted its position in shares of Surmodics by 34.2% in the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after acquiring an additional 880 shares during the period. Strs Ohio acquired a new stake in Surmodics in the 1st quarter worth about $122,000. Price T Rowe Associates Inc. MD bought a new stake in Surmodics in the 4th quarter valued at about $217,000. Polymer Capital Management US LLC acquired a new position in shares of Surmodics during the 4th quarter worth approximately $255,000. Finally, DeepCurrents Investment Group LLC bought a new position in shares of Surmodics during the fourth quarter worth approximately $260,000. Institutional investors own 96.63% of the company's stock.
About Surmodics
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Read More
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
